Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 6Cisplatin 6Nivolumab 5Gemcitabine 5Drug Therapy 5Radiotherapy 4Docetaxel 4pembrolizumab 3Platinum Compounds 3Immune Checkpoint Inhibitors 3Endostatins 3Carboplatin 3tislelizumab 2endostar protein 2durvalumab 2camrelizumab 2Thalidomide 2Paclitaxel 2Oxaliplatin 2Irinotecan 2Gefitinib 2Erlotinib Hydrochloride 2Bevacizumab 2Afatinib 2trilaciclib 1toripalimab 1titanium silicide 1osimertinib 1olaparib 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Carcinoma, Non-Small-Cell Lung × Pharmaceutical Preparations × Clear all
NCT01027676 2013-11-14

Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)

National Cancer Center, Korea

Phase 1/2 Unknown
50 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡